Using the broad targeting nonselective DUB inhibitor PR-619, we observed a clear reduction in IL-32 protein after 2 and 4 h (Figure 4A), indicating that DUBs counteract ubiquitin-dependent degradation of IL-32 in MM cells in normal oxygen conditions. Here, IL32 is linked to Miyoshi myopathy.